Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Medimmune LLC
Headquarters: Gaithersburg, MD, United States of America
Website: N/A
Year Founded: 1988
Status: Acquired
BioCentury | Feb 1, 2025
Finance
Investors with deep China roots lead NewCo surge, inspiring Western VCs
Led by Orbimed, LAV, Boyu, biotech’s Asia ‘NewCo Model’ goes global
BioCentury | Nov 21, 2024
Finance
Versant-backed Pep2Tango taking four-way agonist to clinic for obesity
Program designed to reduce weight while sparing muscle mass, GI effects headed for IND next year
BioCentury | Apr 14, 2023
Management Tracks
Dewhurst leaving McKinsey after 30 years
Plus: Sabet-Peyman now partner at Patient Square and an update from Zura Bio
BioCentury | Jan 15, 2022
Management Tracks
Founder El-Hibri to retire from Emergent
Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie,
BioCentury | May 11, 2021
Emerging Company Profile
DTx: Optimizing RNA therapies for cellular uptake, biodistribution
Emerging Company Profile: DTx is slated to enter the clinic next year with its fatty acid ligand conjugated RNA therapy to treat retinitis pigmentosa
BioCentury | Apr 15, 2021
Emerging Company Profile
How SV-seeded Alchemab is searching for mAbs in super responders
Alchemab attracts RA Capital-led syndicate to £60M series A round
BioCentury | Jun 12, 2020
Product Development
June 11 Quick Takes: Sobi licenses Selecta gout therapy; plus Viela’s first approval, CSL, BMS, Sirnaomics’ spinout, Denali-Sanofi
BioCentury | Mar 10, 2020
Politics, Policy & Law
We’ve moved on from nude women parties. The progress is much bigger than that.
Commentary: Women should be shouting about their wins, and using them as a platform to demand more
BioCentury | Mar 2, 2020
Finance
Immunocore’s $130M series B gives new CEO Jallal capital to progress pipeline
Immunocore's $130M series B will take lead candidate through pivotal Phase II
BioCentury | Sep 19, 2019
Targets & Mechanisms
Regeneron's new take on bispecifics: activating complement
Why Regeneron built a bispecific platform that harnesses the complement system
Items per page:
1 - 10 of 469